On behalf of the Editor-in-Chief, Prof. Dr. Samuel C. Mok, we wish to acknowledge our reviewers who so generously give their time to review papers submitted to Cancers by presenting an award to those reviewers who have demonstrated exceptional dedication, professionalism, and timeliness in reviewing manuscripts for Cancers.

What are the prerequisites to be eligible for this award?
All of the reviewers for Cancers in 2022 will be automatically included.

Select Criteria:
– Number of review reports (only first review reports are considered);
– Review quality based on the rating given in SuSy;
– Review speed.

What will the winners receive?
The Committee will select sixteen dedicated reviewers to receive Recognition Awards for Manuscript Review and four persons to receive the Outstanding Award for Excellence in Manuscript Review.

The Recognition Awards for Manuscript Review will consist of:
– An opportunity to publish a paper free of charge before the end December 2023;
– An electronic certificate.

The Outstanding Award for Excellence in Manuscript Review will consist of:
– CHF 500;
– An opportunity to publish a paper free of charge before the end December 2023;
– An electronic certificate.

When will the winners be announced?
The winners will be announced in March 2023 on the journal website.

How can I make myself eligible?
If you have not yet reviewed papers for Cancers but would like to do so, you can register as a reviewer through the following link: https://susy.mdpi.com/volunteer/profile/edit.

Dear Colleagues,

The journal Cancers is currently inviting applications for the Cancers 2022 Ph.D. Thesis Award. This prize will be awarded to two Ph.D. students or doctors who have produced a highly anticipated academic potential thesis. The applications will be assessed by an evaluation committee, which will be led by the Editor-in-Chief Prof. Dr. Samuel Mok.

Eligibility Requirements:
– The candidate must be a Ph.D. student or a doctor who has produced a highly anticipated academic potential thesis.
– The Ph.D. thesis must be their original work.
– The Ph.D. thesis must be defended between 1 September 2021 and 31 August 2022.
– Applicants are required to submit the following documents:
   – An executive summary of the Ph.D. thesis, of around 3000 words, in English;
   – A letter from the Ph.D. supervisor recommending the candidate for consideration for this award;
   – The candidate’s CV, including a list of publications connected with the thesis;
   – An electronic copy of the Ph.D. thesis;
   – A scanned copy of the Ph.D. diploma (or certificate of studying at a school or research institute as a Ph.D. student who is intending to graduate or participate in graduation thesis defenses).

Selection Criteria:
– Quality of resume and publications;
– Relevance of the candidate and research description;
– Novelty of the candidate’s Ph.D. thesis;
– Strength of the recommendation letter;
– Anticipated academic potential;
– Originality and impact of the research.

Prizes:
There will be two winners, each winner will be awarded:
– Bonus (CHF 800);
– An electronic certificate;
– Offer to publish a featured paper in Cancers, with the article processing charge (APC) waived, before the end of 2023.

The application deadline is 31 October 2022. The winner will be announced on the Cancers website by the end of December 2022.

Please submit your applications via [email protected]

Dear Colleagues,

We are pleased to announce that Cancers is now inviting nominations for the 2022 Young Investigator Award. Prizes will be given to two young investigators in recognition of their excellence in the field of oncology. All nominations will be assessed by an Evaluation Committee led by the Editor-in-Chief, Prof. Dr. Samuel C. Mok.

The Prizes:
There will be two winners, each winner will be awarded:
– 2000 CHF (Swiss francs);
– Option to publish one paper free-of-charge in Cancers after peer review before the end of 2023;
– An electronic certificate.

Eligibility and Requirements:
– Must have PhD degree and be below 35 years of age;
– Must have produced ground-breaking research and a significant contribution to the advancement of oncology;
– Must be nominated by senior researchers, research directors, or department heads.

List of Documents for Nomination:
– Detailed curriculum vitae, including an updated publication list and a list of the researcher’s own research grants;
– Birth certificate or other proof of age;
– Scanned copy of doctorate certificate;
– Signed nomination letters from two established senior scientists.

Schedule:
– Open for nominations: 1 February 2022;
– Nomination deadline: 30 September 2022;
– Winners announced: 30 November 2022.

How to submit nominations:
The nominations must be submitted online.

Dear Colleagues,

As the Editor-in-Chief of Cancers, I am pleased to announce the winners of the Cancers 2022 Travel Awards.

The awards have been granted to Diego de Miguel Perez, a postdoctoral fellow from the Icahn School of Medicine at Mount Sinai, and Luigi Russo, a postdoctoral fellow from the Italian Institute of Technology (IIT).

With so many high-quality applicants, the evaluation process and final decision were challenging. We would like to thank all of the applicants for submitting their diverse and fascinating range of research topics. On behalf of the Assessment Committee, I congratulate the winners on their accomplishments.

Prof. Dr. Samuel C. Mok
Editor-in-Chief, Cancers

Dear Colleagues,

We are pleased to announce the winners of Cancers 2021 Outstanding Reviewer Awards. The Cancers Editorial Board and Editorial Team would like to gratefully acknowledge the time and energy dedicated by reviewers in checking the manuscripts submitted to Cancers. It is due to their efforts that the high quality of the journal and quick turnaround are maintained.

The winners will each receive CHF 500, an electronic certificate, and a chance to publish a paper free of charge in Cancers after peer review in 2022:

Dr. Antonio G. Solimando
Department of Biomedical Sciences and Human Oncology, University of Bari Aldo Moro, Bari, Italy

Dr. Chenghui Li
Department of Pharmacy Practice, University of Arkansas for Medical Sciences, Little Rock, USA

Dr. Joaquim Carreras
Department of Pathology, Tokai University, Isehara, Japan

Dr. Pierfrancesco Franco
Department of Oncology - Radiation Oncology, University of Turin School of Medicine, Turin, Italy

Dr. Laurentiu Pop
Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, USA

Kind regards,
Prof. Dr. Samuel C. Mok
Editor-in-Chief, Cancers

Dear colleagues,

As the Editor-in-Chief of Cancers, it is my great pleasure to announce the winner of the Cancers 2021 Ph.D. Thesis Award. This prize has been awarded to a Ph.D. student who has produced a highly anticipated academic potential thesis.

The award has been granted to:

“Immunological Basis of Abscopal Antitumor Responses Induced by Combination of Distinct Radiotherapy Fractionation Schedules with Autologous Tumor Vaccines and Checkpoint Inhibition” by Dr. rer. nat. Michael Rückert, Translational Radiobiology, Department of Radiation Oncology, Universitätsklinikum Erlangen, Germany.

Dr. rer. nat. Michael Rückert will be awarded 800 CHF and a certificate, and a chance to publish one paper free of charge in Cancers during the period 2021–2022.

On behalf of the evaluation committee, I would like to congratulate Dr. rer. nat. Michael Rückert on his accomplishments. We would also like to take this opportunity to thank all the nominated research groups of the above exceptional thesis for their contributions to Cancers, and thank the Award Committee for voting for and helping with this award.

Prof. Dr. Samuel Mok.
Editor-in-Chief, Cancers

Dear Colleagues,

The editorial team would like to congratulate the winners of the Cancers 2019 Best Paper Awards, who were chosen by a Selection Committee chaired by the Editor-in-Chief, Prof. Dr. Samuel C. Mok. Following a review process by the Evaluation Committee, four winners were selected. The recipients of the “Cancers 2019 Best Paper Awards” are as follows:

Article:

CAR T-Cells Targeting the Integrin αvβ6 and Co-Expressing the Chemokine Receptor CXCR2 Demonstrate Enhanced Homing and Efficacy against Several Solid (doi: 10.3390/cancers11050674)
By: Lynsey M. Whilding, Leena Halim, Benjamin Draper, Ana C. Parente-Pereira, Tomasz Zabinski, David Marc Davies and John Maher
Cancers 2019, 11(5), 674.

Blockade of Lactate Dehydrogenase-A (LDH-A) Improves Efficacy of Anti-Programmed Cell Death-1 (PD-1) Therapy in Melanoma (doi: 10.3390/cancers11040450)
By: Saeed Daneshmandi, Barbara Wegiel and Pankaj Seth
Cancers 2019, 11(4), 450.

Review：

Gut Microbiota and Cancer: From Pathogenesis to Therapy (doi: 10.3390/cancers11010038)
By: Silvia Vivarelli, Rossella Salemi, Saverio Candido, Luca Falzone, Maria Santagati, Stefania Stefani, Francesco Torino, Giuseppe Luigi Banna, Giuseppe Tonini and Massimo Libra
Cancers 2019, 11(1), 38.

PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review (doi: 10.3390/cancers11071033)
By: Gabrielle Planes-Laine, Philippe Rochigneux, François Bertucci, Anne-Sophie Chrétien, Patrice Viens, Renaud Sabatier and Anthony Gonçalves
Cancers 2019, 11(7), 1033.

Each winner (corresponding author) will receive 500 CHF and a chance to publish a paper free of charge in Cancers in 2021 after the normal peer-review procedure.

Please join us in congratulating the winners of Cancers 2019 Best Paper Awards. We would also like to take this opportunity to thank all of our authors for their continued support of Cancers.

Dear Colleagues,

We are pleased to announce the “Cancers 2020 Best Paper Awards” for review and research articles published in Cancers from 1 January 2020 to 31 December 2020. Two reviews and two research articles will receive awards. The papers will be selected after thorough evaluation by the journal Award Committee led by the EiC, Prof. Dr. Samuel C. Mok and the winners will be announced in April 2022.

Eligibility for the Awards:
– Papers published in Cancers from 1 January 2020 to 31 December 2020;
– Open to all career levels;
– Both regular and Special Issue submissions will be considered.

Selection Criteria:
The papers will be selected by the journal Award Committee according to the following criteria (data source: Web of Science (Clarivate Analytics)):
– Scientific merit and broad impact;
– Originality of the research objectives and/or the ideas presented;
– Creativity of the study design or uniqueness of the approaches and concepts;
– Clarity of presentation;
– Citation and download rates in 2021.

Prizes:
– Two review awards: 500 CHF and a chance to publish a free paper in Cancers in 2022;
– Two research article awards: 500 CHF and a chance to publish a free paper in Cancers in 2022.
– Each winner will also receive an electronic certificate.

The winners will be announced on the journal website in April 2022.

Dear Colleagues,

We are pleased to announce the winners of the Cancers 2020 Outstanding Reviewer Awards. The Cancers Editorial Board and Editorial Team would like to gratefully acknowledge the time and energy dedicated by reviewers in checking the manuscripts submitted to Cancers. It is due to their efforts that the high quality of the journal and quick turnaround are maintained.

Dr. Pedro Miguel Rodrigues, Biodonostia Health Research Institute, Spain

Dr. Hua-Sheng Chiu, Texas Children’s Cancer Center, Baylor College of Medicine, Houston, USA

They will receive the following:
– An electronic certificate;
– 1000 Swiss francs (CHF);
– An offer to publish a paper free of charge in Cancers after peer review before the end of 2021.

Kind regards,

Dear Colleagues,

We are pleased to announce that the winners of the Cancers 2020 Young Investigator Awards are Dr. Lukas Bunse and Dr. Ylenia Perone.

Dr. Bunse is a postdoctoral researcher and a team leader at the Clinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center, Germany. Dr. Bunse’s research interests are in oncoimmunology, transgenic cell therapy, and vaccine development. He received his MD (Dr. med) in 2016 and his Ph.D. (Dr. rer. nat.) in 2020 and has an outstanding publication record, comprising 23 publications in peer-reviewed international journals and 2 international patents. Dr. Bunse’s Scopus Scientific Citations number is 1390 and his Hirsch index is 12. He is clearly a rising star in the field of neuro-oncology. As a single applicant, Dr. Bunse has secured funding of more than EUR 1.4 million since 2018.

Dr. Perone MD, Ph.D., is a Clinical Research Fellow in Medical Oncology at the Imperial College London, UK. Dr. Perone’s research interests range from clinical research and clinical trials to basic scientific research in the endocrine-related cancer field. Dr. Perone was awarded a prestigious Cancer Research UK (CRUK) Ph.D. Fellowship at Imperial College London and received her Ph.D. degree in 2020. Her research aimed to understand the interplay between epigenetics and lipid metabolism in endocrine therapy-resistant nuclear receptor-positive cancer. She is clearly a rising star in the field with an outstanding record of achievement for a young investigator at this stage of her career comprising ten publications in peer-reviewed international journals, two invited oral presentations at International Conferences, and twelve Awards and Prizes.

This is an outstanding achievement in today’s competitive environment. Please join us in congratulating Dr. Bunse and Dr. Perone for their outstanding achievements.

As the awardee, Dr. Bunse and Dr. Perone will receive an honorarium of 2000 CHF, an offer to publish a paper free of charge before 2021 in Cancers after peer review, and an electronic certificate.

We would like to thank all the nominators and nominees from various fields of study for their participation and all the Award Committee Members for their evaluation of the many excellent nominations.

The following four nominees will be given a 15% discount on a paper to be published in Cancers in 2021.

• Arutha Kulasinghe, Queensland University of Technology, Australia
• John Charles Rotondo, University of Ferrara, Italy
• Mohamed Saad, Monash University, Australia

Prof. Dr. Samuel C. Mok
Editor-in-Chief, Cancers

Dear Colleagues,

We are pleased to announce that the winner of the 2018 Cancers Young Investigator Award is Dr. Sarah McClelland. Dr. McClelland will receive an award of 2000 Swiss Francs, an offer to publish a paper free of charge without a fixed deadline in Cancers, and an engraved plaque.

Dr. Sarah McClelland is a lecturer in Molecular Oncology at the Barts Cancer Institute, Queen Mary University of London. Dr. McClelland received her Ph.D. degree in 2003 and worked as a postdoctoral research fellow from 2003 to 2013. In 2013 she established her laboratory at the Barts Cancer Institute, Queen Mary University of London. Here, her research aims to understand causes of chromosome mis-segregation in the context of ovarian and pancreatic cancer, and also to characterise fundamental mechanisms controlling genetic stability. Her laboratory recently discovered that individual human chromosomes behave non-randomly during error-prone mitosis, which has important implications for understanding the widespread chromosome changes in cancer. Dr. McClelland’s track record of achievements is impressive for a young investigator at this stage of her career.

We would like to thank all the applicants in various fields of study for their participation and the Award Committee members for reviewing the numerous high-quality applications received.

Prof. Dr. Samuel C. Mok
Cancers Editorial Office
Editor-in-Chief

Dear Colleagues,

As Editor-in-Chief of the open access journal Cancers, it is my pleasure to announce that the winner of the 2017 Cancers Travel Award is Dr. Cecilia Leung, Ph.D. Dr. Leung is a postdoctoral researcher in Prof. Giulio Draetta’s laboratory at the University of Texas MD Anderson Cancer Center, Houston, TX, USA.

On behalf of Cancers, she will be supported with 1000 Swiss Francs towards travel expenses to attend the American Association for Cancer Research (AACR) Annual Meeting 2017 to be held at Washington, D.C., USA.

Dr. Leung’s current research focuses on epigenetic regulation of pancreatic cancer progression. Using pooled shRNA epigenome library, she and her colleagues performed an in vivo loss-of-function screen and identified COMPASS-like complexes, which have specific H3K4 methyltransferase activity, to be key oncogenic drivers of pancreatic cancer. Dr. Leung has co-authored ten publications of which three are as first author, many in high profile journals (such as Nature Communications, Cancer Research and Clinical Cancer Research). She has also already been the recipient of numerous awards.

Prof. Samuel C. Mok
Editor-in-Chief